Expect ‘high tide’ of Chinese biotech deals as threat of US curbs fades: analysts

AI Summary

Chinese biotech deals with the US are expected to increase as Washington appears to be easing restrictions, boosting Chinese healthcare firms. This optimism follows China's ambitious five-year plan for its biotech sector, with analysts forecasting a surge in out-licensing deals.

US-China biotech deals are expected to thrive because Washington is reportedly leaning away from sweeping restrictions, according to analysts, giving Chinese healthcare firms a major boost following Beijing’s ambitious five-year plan for the sector. Out-licensing deals between China and the US would “ride on a high tide” in the favourable environment, said Nomura’s head of China healthcare research Jialin Zhang, in a research note on Sunday. The US Treasury Department was drafting investment...